The drug major announced the launch of mycophenolate mofetil tablets USP, 500 mg, after its alliance partner Concord Biotech received an approval for its ANDA from the United States Food and Drug Administration (USFDA).
The product is the generic equivalent of CellCept tablets of Roche Palo Alto LLC, indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.
As per IQVIA MAT October 2020 data, mycophenolate mofetil tablets USP (RLD: CellCept) had an annual sales of approximately $87 million in the U.S. The announcement was made during market hours today, 29 December 2020.
Shares of Lupin fell 0.52% to Rs 978.90 on BSE.
On a consolidated basis, the drug major reported a net profit of Rs 213.51 crore in Q2 FY21 compared with net loss of Rs 123.44 crore in Q2 FY20. Net sales during the quarter declined 1% year-on-year (Y-o-Y) to Rs 3,781.80 crore.
Lupin is an innovation-led transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app